Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 nov. 2019 16h40 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of an aggregate of 14,700...
Flexion Therapeutics to Report Third-Quarter 2019 Financial Results on November 7, 2019
31 oct. 2019 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2019 financial results after the close of the U.S....
Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis
31 oct. 2019 07h30 HE
|
Flexion Therapeutics, Inc.
In addressing a highly prevalent, non-monogenic musculoskeletal disease, FX201 has the potential to open a new treatment avenue for gene therapy A single intra-articular injection of FX201 has the...
Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®
14 oct. 2019 07h00 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has informed the company it needs...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 oct. 2019 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 80,550 stock...
Former NY Yankees Outfielder Chris Dickerson Teams Up With Flexion Therapeutics to Raise Awareness of Impact of Osteoarthritis (OA)
02 oct. 2019 09h00 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics (Nasdaq:FLXN) is teaming up with Chris Dickerson, a former New York Yankees outfielder and member of the 2011 and 2012...
Flexion Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa
30 sept. 2019 09h04 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at...
Flexion Therapeutics Sponsors a Memorial to the Victims of the Opioid Crisis to Raise Awareness of the Tragic Consequences of the Opioid Epidemic Across the U.S.
23 sept. 2019 09h00 HE
|
Flexion Therapeutics, Inc.
Interactive memorial developed by the National Safety Council pays tribute to more than 22,000 victims of the opioid crisis and offers resources to help stem the epidemicExhibit will be on display...
Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain
09 sept. 2019 16h01 HE
|
Flexion Therapeutics, Inc.; Xenon Pharmaceuticals Inc.
Flexion’s new locally delivered product candidate, FX301, will combine Xenon’s NaV1.7 inhibitor, XEN402, with a novel thermosensitive hydrogelFX301 is a potential first-in-class therapy with the aim...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 sept. 2019 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to nine new employees consisting of an aggregate of 25,900...